key: cord-0944222-t5qkygva
authors: Barros, Inês; Silva, António; de Almeida, Luís Pereira; Miranda, Catarina Oliveira
title: Mesenchymal stromal cells to fight SARS-CoV-2: Taking advantage of a pleiotropic therapy
date: 2020-12-15
journal: Cytokine Growth Factor Rev
DOI: 10.1016/j.cytogfr.2020.12.002
sha: 234d053ae438b10e8891059b46af1cf85cd1e0ad
doc_id: 944222
cord_uid: t5qkygva

The devastating global impact of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has prompted scientists to develop novel strategies to fight Coronavirus Disease of 2019 (COVID-19), including the examination of pre-existing treatments for other viral infections in COVID-19 patients. This review provides a reasoned discussion of the possible use of Mesenchymal Stromal Cells (MSC) or their products as a treatment in SARS-CoV-2-infected patients. The main benefits and concerns of using this cellular therapy, guided by preclinical and clinical data obtained from similar pathologies will be reviewed. MSC represent a highly immunomodulatory cell population and their use may be safe according to clinical studies developed in other pathologies. Notably, four clinical trials and four case reports that have already been performed in COVID-19 patients obtained promising results. The clinical application of MSC in COVID-19 is very preliminary and further investigational studies are required to determine the efficacy of the MSC therapy. Nevertheless, these preliminary studies were important to understand the therapeutic potential of MSC in COVID-19. Based on these encouraging results, the United States Food and Drug Administration (FDA) authorized the compassionate use of MSC, but only in patients with Acute Respiratory Distress Syndrome (ARDS) and a poor prognosis. In fact, patients with severe SARS-CoV-2 can present infection and tissue damage in different organs, such as lung, heart, liver, kidney, gut and brain, affecting their function. MSC may have pleiotropic activities in COVID-19, with the capacity to fight inflammation and repair lesions in several organs.

multipotent stem cells with the ability to differentiate into other cell types and be used for cell replacement therapy. Furthermore, MSC secrete a wide range of paracrine factors, which can modulate inflammation and promote tissue regeneration ( Fig. 1) [4] . Indeed, regardless of the organ, SARS-CoV-2 infection causes disseminated inflammatory reactions, so therapies that bear immunomodulatory effects are welcome to treat COVID-19. Corroborating this idea, several clinical trials using MSC or their derived products are now ongoing and eight clinical studies were already concluded and reported interesting results, as most COVID-19 patients recovered a few days after treatment [5] [6] [7] [8] [9] [10] [11] [12] . However, only one of these studies incorporated appropriate control groups and a considerable number of patients. The urgent need to perform larger clinical studies with suitable cohorts are here discussed.

This review discusses the main injuries in organs infected by SARS-CoV-2 and highlights the possible application of MSC to COVID-19 patients by addressing putative mechanisms of these cells or their secretome/Extracellular Vesicles (EVs), based on information of their use in similar pathologies. Anticipated issues are also discussed in order to optimize future therapeutic designs

An outbreak of atypical pneumonia, now known as COVID-19, upsurged in the city of Wuhan, China, in December 2019. The disease rapidly spread throughout the world and as of 30th November 2020, more than 62 M people have been diagnosed with COVID-19 and over 1.4 M of deaths were confirmed worldwide (coronavirus.jhu.edu/map. html). The pathogenic agent was quickly identified as SARS-CoV-2, a relative of the coronaviruses that caused the SARS outbreak in 2003 (79.5 % genetic similarity) and the Middle East Respiratory Syndrome in 2012 (50 % genetic similarity) [13, 14] . SARS-CoV-2 is a betacoronavirus, possessing a positive single-stranded RNA and a total genome of 29,881 bp [15] . Like other coronaviruses, it has a nucleocapsid protein, membrane and spike glycoproteins and another glycoprotein with acetyl esterase and hemagglutination properties [16] .

This novel virus likely originated from bats (as it is closely related with two other bat-derived SARS-like coronaviruses, the bat-SL-CoVZC45 and the SL-CoVZXC21) and may have passed to an unknown reservoir animal; then jumped to humans and promptly spread due to human-to-human transmission through direct contact or droplets [13, 14] . On average, the incubation period of COVID-19 is 4 days and it has also been reported that some patients are asymptomatic but can transmit the virus [17, 18] .

SARS-CoV-2 enters the cells after binding to the Angiotensin-Converting Enzyme 2 (ACE2) through its spike glycoproteins; additionally, the cellular Transmembrane Protease Serine 2 (TMPRSS2) has been shown to play a role in infection [19] . SARS-CoV-2 has the potential to infect cells in tissues where these receptors are widely expressed including the lungs, heart, kidneys, liver, gut and even the brain [1] [2] [3] . The main symptoms of COVID-19 are dry cough, fever, fatigue and shortness of breath, along with anosmia and ageusia. Some of the minor symptoms include headache, diarrhea and nausea [20] . The majority of patients have light manifestations of the disease without much requirement for medical assistance. However, in severe cases, patients may develop ARDS, arrhythmia, neurological symptoms, septic shock and metabolic acidosis [17, 21, 22] . Upon infection, SARS-CoV-2 elicits an initial adaptive immune response that is developed during earlier stages to eliminate the virus. However, patients with dysfunctional bridge in adaptive immunity exhibit an exacerbated innate immune response, generating high levels of free radicals which can culminate in multi-organ failure and death [23] [24] [25] . Biochemical analyses showed that most COVID-19 patients have decreased lymphocyte and leucocyte counts as well as increased levels of C-reactive protein (inflammation marker) and lactic dehydrogenase [20, 24] . Moreover, ACE2 and ACE, a homologous protein, are both involved in regulating the renin-angiotensin system (RAS), which controls blood pressure and ensures the maintenance of endothelial tissue. When SARS-CoV-2 binds to ACE2, the receptor becomes downregulated and RAS is highly 19 . Upon entering the body, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is able to infect multiple organs (lungs, heart, liver, kidneys, gut and brain) by binding to Angiotensin-Converting Enzyme (ACE2) through its spike glycoproteins. ACE2 modulates the renin-angiotensin mechanism, thus the presence of the virus can lead to dysregulations in blood pressure. Moreover, SARS-CoV-2 can evoke an exacerbated inflammatory response which may lead to multi-organ injury. Besides, extensive damage in the parenchyma can increase the risk of opportunistic infections. MSC therapy is a promising treatment for COVID-19 as they exert potent anti-inflammatory and antimicrobial actions and promote tissue repair and regeneration through the secretion of soluble factors, extracellular vesicles and direct cell-to-cell contact. disturbed. This mechanism can lead to vasoconstriction, enhanced inflammation and thrombosis [26] . Thus, patients with hypertension or cardiovascular disorders are risk groups for COVID-19. Nonetheless, even though SARS-CoV-2 can infect people of all ages and sexes, the most severe cases usually occur in elder patients and/or patients with comorbidities (e.g., chronic diseases, cancer, obesity, diabetes) [20, 21] .

Unfortunately, there is still no specific treatment. Hand disinfection, social distancing and the use of masks [27] are the recommended preventive tools so far. Additionally, patients are provided with adequate supportive care and treated for secondary infections. The efficacy of several existing treatments used in other diseases such as antivirals (Remdesivir, Favipiravir, Lopinavir/Ritonavir), anti-inflammatory drugs (glucocorticoids and hydroxychloroquine), and plasma transfusion from recovered patients has been investigated for COVID-19 [28, 29] . Nevertheless, the available data is scarce regarding their efficacy and some drugs initially thought to be effective have now shown disappointing performances, as the case of hydroxychloroquine, Lopinavir/Ritonavir and Remdesivir [28, 30, 31] .Currently, a high number of preventive vaccines are being tested and some were shown to be safe and highly effective in conferring immunity against SARS− COV-2 (modernatx.com; pfizer.com [32] ).

However, these vaccines still need to be approved by the regulatory authorities and the widespread distribution and administration of vaccines is necessary in order to confer herd immunity. This process will take time to be completed, so effective therapies are needed for the time being. The use of cell therapy in COVID-19, particularly with MSC, demonstrated promising outcomes on preliminary clinical reports [5] [6] [7] . Additionally, MSC can be used in conjugation with other favourable therapies, amplifying the treatment's efficacy.

MSC are multipotent stem cells that must meet a minimum criteria to be distinguished from other cell types [33] : 1) Plastic adherence; 2) Surface expression of CD105, CD73, CD90, and lack of CD45, CD34, CD14, CD19 and HLA-DR; 3) in vitro differentiation into osteoblasts, adipocytes and chondroblasts. They are found in various tissues throughout the body being the most common sources, for research and clinical purposes, bone marrow (BM-MSC), umbilical cord (UC-MSC) and adipose tissue (AD-MSC). Importantly, both allogeneic and autologous transplants are possible as MSC have a low immunogenicity [34] . MSC are commonly administrated through intravenous (IV) injection, although other routes might be more appropriated according to the target organ.

MSC have been extensively researched for their ability to generate strong immunomodulatory and regenerative effects in damaged tissues [4] . This therapeutic potential depends on the microenvironment in which MSC are placed as their response is very sensitive to factors such as the extracellular matrix and substances released by other cells; therefore, they can have highly adaptative responses to different cellular contexts [35] . In fact, the presence of inflammatory factors may alter MSC secretion profile towards a greater immunomodulatory action [36] . In agreement, cultured MSC can also be stimulated by different pre-conditioning protocols to release a myriad of cytokines, growth factors, and EVs containing miRNAs that are relevant for mechanisms involved in inflammation [37] . The EVs and conditioned medium obtained can similarly be used as a cell-free alternative to exploit the strong paracrine communication of MSC without the ethical, technical, and physiological complications that may arise from stem cell transplantation at the clinical level [38] .

For the time being it seems the lungs are the most affected organ in COVID-19 patients, as ARDS is a significant symptom amongst the patients that develop a severe form of the disease [17] . Indeed, the ACE2 receptor, to which SARS-CoV-2 binds, is widely expressed at the surface of lung alveolar type II and capillary endothelial cells [39] . In the lungs, SARS-CoV-2 can elicit a cytokine storm with secretion of high levels of pro-inflammatory cytokines such as Interleukin (IL) 1β, IL-1 Receptor  Antagonist (IL-1RA), IL-2, IL-6 , IL-7, Granulocyte Colony-Stimulating Factor (GCSF), Interferon (IFN) ϒ and Tumor Necrosis Factor (TNF), as well as infiltration of neutrophils and macrophages in alveolar space [24, 40] . This prolonged exacerbated inflammatory response enhances the production of reactive oxygen species that damage the lung tissue and lead to ARDS, which is characterized by pulmonary edema, arterial hypoxia and dysfunction of air exchange function [5, 41] . Moreover, the presence of the virus in the lungs also increases the risk of secondary infections [1] .

Over the last decades, the therapeutic potential of MSC for the treatments of severe respiratory illnesses has been extensively investigated in pre-clinical studies, namely in ARDS animal models using various injury-inducing mechanisms, including viral infections. MSC are believed to promote a multitude of beneficial actions providing support not only by modulating the immune response and inflammation, but also by promoting tissue repair, impeding fibrosis and improving pulmonary dysfunction [4, 42] . A meta-analysis of 57 studies that investigated the efficacy of MSC transplantation in ALI/ARDS animal models revealed that MSC can reduce lung injury, improve lung compliance and animal survival in part by modulating inflammation [43] .

The administration of MSC has been shown to reduce Acute Lung Injury (ALI) induced by influenza virus H9N2 and increase mice survival, mainly by attenuating the host inflammatory response. MSC were able to modulate the levels of chemokines (Granulocyte-Macrophage Colony-Stimulating Factor, Monocyte Chemoattractant Protein-1 (MCP-1), Chemokine CXC Motif Ligand 1, Macrophage Inflammatory Protein 1α and Monokine Induced by Gamma Interferon) and cytokines (IL-1α, IL-6, TNF-α, and IFN-ϒ) that greatly contribute to ALI development. An increased expression of IL-10, an anti-inflammatory cytokine was also observed [44] . The higher expression of this specific cytokine may be explained by MSC production of prostaglandin E 2 which can reprogram macrophages to increase their secretion of IL-10 [45] . Moreover, Busto et al. showed that MSC pre-activated by explosion to ALI patients' serum expressed high amounts of IL-10 and IL-1RA, which were linked to MSC ability to reduce pulmonary edema and infiltration of inflammatory cells and cytokine production [46] . Accordingly, MSC have been shown to protect lungs from bleomycin-induced injury (a model of ALI) by expressing IL-1RA which can decrease macrophages' secretion of TNF and inhibit proliferation of T-cell [47] . Another anti-inflammatory protein that contributes to MSC ability to reduce ALI is TNF-α-induced protein 6 [48] .

Another important action of MSC in the treatment of ARDS is their antimicrobial effect. Indeed, MSC can enhance the phagocytic activity of host monocytes, neutrophils and macrophages [49, 50] . These antimicrobial actions have been linked to MSC production of LL-37, Lipocalin-2 and Fibroblast Growth Factor 7 (FGF7), as the use of blocking agents for these peptides nullified the protective effect of MSC in in vivo and ex vivo models of lung injury [49, 51, 52] . Furthermore, it has been demonstrated that mitochondria transference from MSC to macrophages -through tunneling nanotube-like structures or via EVs -also plays an important role in the increment of their phagocytic activity in ARDS [53, 54] . In cases of viral-induced injury such as COVID-19, this action could be crucial to prevent or treat opportunistic bacterial infections.

Furthermore, several studies have shown that MSC and its secretome are able to promote tissue repair and regeneration in models of ALI and ARDS [55, 56] . Indeed, MSC secrete Angiopoietin-1 and FGF7 (also known as Keratinocyte growth factor) which promote stability of endothelial cells, thereby repairing the alveolar-capillary barriers, increasing alveolar fluid clearance and reducing pulmonary edema [56] [57] [58] . Additionally, MSC have been shown to repair alveolar cells by mitochondrial transfer through direct cell-to-cell contact, increasing their bioenergetic levels [59] . MSC may also protect pulmonary cells by increasing autophagy via phosphoinositol 3-kinase/protein B pathway [60] .

The generally promising pre-clinical findings prompted the design of several clinical trials to investigate the therapeutic potential of MSC for the treatment of ARDS. These studies primarily aimed at evaluating the safety of this approach, showing that MSC transplantation in ARDS patients is safe, since no major side effects related to MSC infusion have been reported [61] [62] [63] [64] . Indeed, a phase I clinical study that tested three doses of BM-MSC in patients with moderate to severe ARDS showed that BM-MSC administration was well tolerated even at the highest dose [63] . A description of the experimental conditions in the mentioned clinical trials is given in Table 1 .

Clinical effects of MSC in ARDS/ALI were not always consistently found in the literature. In 2014, Zheng and collaborators demonstrated that Adipose-derived (AD)-MSC transplantation decreased inflammation; however, under their experimental conditions, the beneficial outcomes were weak [61] . Moreover, in a phase IIa double-blind placebo-controlled clinical trial, Matthay and colleagues did not find significant favorable effects [65] . Importantly, it was pointed out that MSC viability had to be improved in future studies, since it ranged from 36 % to 85 % after thawing. The primary aim of this study was to evaluate safety and the same group will further assess the efficiency of the approach in a larger phase IIb clinical trial (NCT03818854).

In contrast, Simonson et al. demonstrated that BM-MSC infusion promoted improvements in respiratory and hemodynamic function, decreased inflammation levels and avoided multi-organ failure in 2 severe refractory ARDS patients [62] . Corroborating these results, another study showed that MSC from Menstrual Blood (MB-MSC) could ameliorate ARDS induced by the bird flu virus H7N9 infection as MB-MSC led to a reduction in mortality (54.5 % in the control group vs 17.6 % in the treated group) [64] .

Overall, there is evidence that MSC are safe and may be beneficial in inflammatory lung injuries even though further investigation is necessary in order to clarify what are the optimal therapeutic conditions. MSC exert important anti-inflammatory, antimicrobial and reparative actions which could be of great help in the treatment of COVID-19 patients Table 1 Concise information of some clinical trials performed with MSC in pathologies that affect the lungs, heart, liver, kidneys, gut or brain, and share disease mechanism with COVID-19. Most clinical trials include a control/placebo group except for the ones mentioned. exhibiting ARDS symptoms [66] [67] [68] .

Several reports have shown that COVID-19 is associated with cardiovascular complications such as arrythmia [2, 69] , myocarditis [70, 71] , acute coronary syndrome [72] , coagulopathies [69, 73] , and Kawasaki syndrome [73] . The origin of these clinical manifestations is somewhat questionable, as it may be a consequence of direct infection of cardiac tissue [74] , systemic inflammation and multi-organ injury, or combination of both. Nevertheless, a retrospective analysis indicates that mortality is very high in patients with myocardial injury associated with COVID-19 (37.5 % in this study).

MSC or their derived products have shown protective effects in a large range of cardiovascular diseases due to their immunomodulatory, antifibrotic, neoangiogenic, and antiapoptotic potential [75] [76] [77] . As an example, AD-MSC can suppress severe coronary arteritis in mice with experimental Kawasaki syndrome by lowering the levels of IL-1B, IL-12, IL-17, C-C Motif Chemokine Ligand 5, INF-ϒ, and TNF-αa, therefore reducing systemic inflammation [78] . Moreover, the use of MSC [79] presents encouraging results in murine models of viral myocarditis caused by Coxsackievirus b3 (+SSRNA) through immunomodulatory mechanisms. Exosomes were also able to regulate autophagy in this model by modulating the 5 ′ AMP-activated Protein Kinase/Mammalian Target of Rapamycin pathways and reducing apoptosis of cardiomyocytes [80] .

So far, most clinical trials using MSC are focused on ischemic/nonischemic cardiomyopathy [81] and myocardial infarction [82] ( Table 1) . A meta-analysis of 9 clinical trials compared different delivery approaches (IV, trans-endocardial, or intracoronary), donor (allogenic or autologous) and tissue source (BM-MSC or UC-MSC) [83] . The overall rate of death for patients with systolic heart failure was shown to be reduced by 36 % and up to 70 % in the intracoronary injection subgroup. Additionally, allogeneic were more effective than autologous MSC and the 6-minutes' walk test and Left Ventricle Ejection Fraction (LVEF) were significantly improved in treated patients. There were no significant differences in efficacy between different tissue sources although the readmission rate was lower in the BM-MSC subgroup. Another analysis of 23 clinical trials, focusing on acute myocardial injury or ischemic heart failure [84] , conducted with MSC from different sources (BM-MSC, UC-MSC or AD-MSC) and administration routes (IV, intracoronary, intramyocardial, endocardial, or epicardial) also found an improvement in LVEF but not in mortality. UC-MSC and intracoronary administration were more effective than other procedures. No major adverse effects were reported except for a mild and short fever in the first study [83] and some neurological delayed adverse effects (of unspecified nature) in the second, although these were rarely correlated with MSC treatment [84] .

Hence, pre-clinical data suggests that MSC or MSC-derived products could have cardioprotective effects against SARS-CoV-2 by reducing the levels of pro-inflammatory cytokines, inhibiting apoptosis, enhancing angiogenesis [76] , and polarizing macrophages towards an anti-inflammatory state [77] , in agreement to what has been observed in other pathologies where the heart tissue is also inflamed. Clinical data also suggests that MSC might be able to improve heart's mechanics [84] and reduce mortality [83] . Therefore, MSC may be beneficial in COVID-19 patients with associated heart failure.

Research in ex vivo models of COVID-19 using human liver duct organoids suggests the possibility of direct liver injury through infection and apoptosis of cholangiocytes in the bile ducts [85] . To support these claims, cholestasis and hepatitis were already described in association with COVID-19 [86] . The bile ducts, which have higher ACE2 expression than hepatocytes [87] , are particularly affected in severe patients. Despite these suggestive facts, liver injury may also be promoted by sepsis or hepatoxic drugs administered as standard medical care.

Pre-clinical studies involving the use of MSC in animal models of sclerosing cholangitis showed positive effects mainly through immunomodulation of T helper (Th) cells [88] , reduction of Cytokeratin 19, Metallopeptidase 9, TNF-α, MCP-1, and improvement of monocyte infiltration in bile ducts [89] . Thus, in inflammatory conditions, MSC are able to decrease inflammation and apoptosis of cholangiocytes while improving the bile duct mechanics.

Moreover, some clinical studies revealed that MSC can ameliorate acute-on-chronic liver failure associated with Hepatitis B virus [90] ( Table 1 ). This type of infection can lead to fibrosing cholestatic hepatitis -a type of severe cholestasis with high mortality [91] . Indeed, a meta-analysis of 3 Chinese clinical trials found a significant decrease in mortality (52.3 %-23.1 %) and hepatic inflammation markers 12 weeks post-treatment with MSC of either allogeneic or autologous source [90] . Despite the potential benefits in terms of enhancing patients' life quality and prognosis, more trials with larger cohorts are required to consolidate these findings.

Even though the use of MSC in hepatic conditions is yet preliminary, the immunomodulatory and regenerative effects described above could be beneficial in COVID19 patients experiencing hepatic injury.

The kidneys are one of the most afflicted organs during COVID-19 infection. Acute Kidney Injury (AKI) has been reported in a high percentage of patients admitted to intensive care with most of them requiring renal replacement therapy [92] . The presence of urinary sodium <35 mEq/l associated with high urine-specific gravity observed in many COVID-19 hospitalized patients is indicative of pre-renal causes of AKI, although it may also appear in certain types of acute tubular necrosis [93] . A high number of viral particles is present in post-mortem analysis of renal cells, suggesting a possible relation between viral infection and necrosis in proximal tubule endothelial cells [92] , where the expression of ACE2 is higher than in type II pneumocytes [94] . Moreover, complement activation, coagulopathy, and endothelial dysfunction may be relevant for the establishment of AKI in COVID-19 patients [95] .

Over the last decades, various pre-clinical studies showed that MSC have nephroprotective effects in models of AKI induced by chemotherapy (cis-platinum), ischemic reperfusion, or renal transplantation through several mechanisms such as immunomodulation, inhibition of apoptosis, and promotion of angiogenesis [96] . Furthermore, some studies have emphasized the important role of MSC-derived EVs [97, 98] . These vesicles carry miRNAs that can alter the expression of genes involved in cellular adhesion and extracellular matrix remodeling in tubular epithelial cells, contributing to kidney regeneration [99, 100] .

In light of the regenerative properties mentioned above, a few clinical trials investigating the use of MSC to treat Chronic Kidney Disease (CKD) or AKI have been registered in clinicaltrials.gov (Table 1) . However, so far only two studies in AKI have published results and even though MSC were safe in both, the results were somewhat contradicting and the authors didn't report any objective biochemical parameter. In a phase I study, infusion of allogeneic BM-MSC via the suprarenal aorta prevented the deterioration of kidney function in cardiac surgery patients at high risk of developing AKI [101, 102] . The hospitalization time and hospital readmission rate decreased approximately 40 % when compared with well-matched historical case-control from the same institution [101] . Contrarily, in a phase II study, Swaminathan et al. did not find any differences regarding the number of days to recover and mortality rate 30 days after treatment with allogeneic MSC through intra-aortic administration [102] .

Thus, the relevance of MSC in promoting regeneration of renal tubular cells has been demonstrated in pre-clinical studies and their administration shown to be safe in subsequent clinical trials with AKI patients. An ongoing clinical trial is set to investigate the efficacy of MSC therapy in COVID-19 patients with AKI (NCT04445220).

The gut is another organ that can be severely damaged by SARS-CoV-2 [103] . Indeed, it has been described that gastrointestinal (GI) alterations appear as early symptoms in the course of COVID-19 disease [104] . Clinical studies reported that GI symptoms are present in a relatively high percentage of COVID-19 patients and may contribute to viral spread by fecal-oral transmission [105, 106] . Indeed, deep alterations in gut microbiota were reported in COVID-19 [107] and some infected patients presented SARS-CoV-2 mRNA in stool, even after the nasopharyngeal symptoms had disappeared and they were considered recovered from the disease [108] . Corroborating these statements through elegant assays performed in human gut organoids, Clever's Lab showed that human gut enterocytes can be actively infected by SARS-CoV-2 and also support viral replication [109] .

MSC therapeutic application for inflammatory gut conditions showing similar symptoms to COVID-19 has been extensively evaluated. In Inflammatory Bowel Disease (IBD), MSC have been proposed to exert a therapeutic effect in dysbiosis by 1) regulating inflammation; 2) potentiating the restoration of diversity and composition of colonic bacteria; 3) promoting the eradication of pathogenic bacteria; 4) inducing tissue remodeling, due to their strong immunomodulatory and tissue regenerative potential [110, 111] . An interesting study analyzed the effects of CM-MSC in an experimental colitis model and found that pleiotropic gut trophic factors are released by these cells. Specifically, Wingless-related Integration Site and Secreted Frizzled-related Protein were identified to be important regulators of epithelial cell proliferation and differentiation, whereas Vascular Endothelial Growth Factor (VEGF) and MCP-1 induced basement membrane angiogenesis and remodeling, respectively [112] .

The immunosuppressive effects in CD's mucosal T cells were evaluated in ex vivo cultures. MSC effect was highly dependent on IDO and cell-cell contact [113] . By performing co-cultures with T cells from CD mucosa, the authors realized that in the presence of MSC the activated subset of CD4+CD25+ T cells was reduced whereas the CD3+CD69+ population increased. Moreover, these cells promoted the secretion of the pro-inflammatory cytokines TNF-α, IFN-γ, IL-17A, IL-21, and over-expression of the Transforming Growth Factor-β and IL-6. These effects were almost eradicated by blocking IDO [113] . Another study demonstrated that the anti-inflammatory response of MSC is dependent on secreted MCP-1 and C-X-C motif chemokine 12 [114] . Overall, MSC anti-inflammatory effects relied on the following actions: M1 macrophages; Dendritic Cells (DCs); CD4+Th1 and Th17 cells, which are able to change their phenotype into immunosuppressive M2 macrophages, tolerogenic DCs and Treg cells, as shown by several groups [45, [115] [116] [117] .

Lately, their application in IBD has even been tested in clinical trials (clinicaltrials.gov), but only a Phase I and a Phase II studies presented reports [118, 119] (Table 1) . The Phase I clinical study aimed at evaluating the safety/tolerability of three different doses of autologous BM-MSC and concluded that no toxicity associated with dose was found while 41,7 % of the patients presented clinical response 2 weeks after the treatment [119] . In the Phase II trial, allogeneic MSC were administered into patients with CD and reduced CD indexes of severity scores in patients presenting luminal CD not responding to biologic therapy [118] . In both studies, the serious adverse effects that were reported in 16,7 % and 6,3 % of patients respectively, were directly related with pre-existing complications in CD (2 dysplasia-associated lesions, need for surgery and risk of bacterial infections such as C. difficile that are known to be elevated in moderate to severe CD).

Therefore, pre-clinical and clinical studies show the feasibility and potential therapeutic effect of MSC treatment for GI inflammatory conditions. Importantly, these conditions are similar to the ones present in SARS-CoV-2 infected patients.

The neuroinvasive role of SARS-CoV-2, also underestimated at the beginning of the pandemic, became evident when the loss of smell and taste in COVID-19 patients was first reported, implicating an involvement of neuronal circuits [120] . Ever since, several other symptoms such as headache, dizziness, depression, encephalitis, stroke, epileptic seizures, and Guillain-Barre syndrome have been reported, demonstrating that the central nervous system can be severely impaired in COVID-19 patients [22] .

Two main hypotheses have been proposed for brain entry and propagation throughout the central nervous system: 1) via the bloodstream; 2) through the olfactory epithelium of the nasal cavity and olfactory bulb via retrograde transport along axons of olfactory sensory neurons [22, 121, 122] . On the other hand, recent evidences support the theory of direct neurotropism of SARS-CoV-2, as the RNA of this virus was detected in the cerebrospinal fluid of a patient with COVID-19 [22] . Moreover, sincethe ACE2 receptor is expressed in brain endothelium, SARS-CoV-2 can enter into the CNS by interacting with ACE-2 of the capillary endothelium leading to blood-brain-barrier (BBB) disruption. BBB can also be damaged by neuroinflammation as a result of the cytokine storm [122, 123] .

The BBB is affected in many viral infections, compromising the brain homeostasis and function [124] [125] [126] [127] [128] [129] [130] . If this is the case MSC can also help reducing viral invasion, as the capacity of MSC or their derived products to recover the BBB has been widely disclosed for different neurological contexts [131] [132] [133] [134] [135] . A pre-clinical study with mice intraperitoneally infected with Japanese Encephalitis Virus (JEV) evidenced that MSC can protect BBB, alleviate JEV-induced inflammation, reduce microglia activation and consequent neuronal damage. In fact, viral load was significantly decreased in this mouse model as well as mortality rate [136] . Furthermore, through in vitro co-culture experiments, the authors detected that the presence of MSC induced reprogramming of microglia from M1 to M2 and decreased viral load, while increasing the expression of INF-α/β in Neuro2a cells [136] . Another set of pre-clinical studies also evaluated the efficacy of MSC in reducing depression in mouse models for Malaria [137] , major depressive disorder [138] and chronic mild stress [139] , all showing that MSC were able to dimmish depressive-like behaviors in the respective models. Interestingly, these studies proposed a common action mechanism of MSC that correlated with the microglial polarization from M1 to M2 phenotype, and down-regulation of TNF-α, IL-1β, and IL-6 (and MCP-1 in the last study). Depression has been highly correlated with inflammatory processes. Thus, it makes sense that MSC can turn down depressive symptoms by normalizing the triggering pro-inflammatory effectors. Pre-clinical studies thus revealed that MSC can in fact lessen depression and encephalitis, two neurological symptoms of COVID-19.

Stroke is a relatively prevalent symptom among COVID-19 patients. A retrospective, observational study reported that of 219 patients with COVID-19, 10 developed acute ischaemic stroke (4.6 %) and 1 had intracerebral haemorrhage (0.5 %). These patients were older and were more likely to have cerebrovascular risk factors, such as hypertension, diabetes and medical history of cardiovascular disease [140] . Importantly, a few clinical studies have reported that MSC therapy for ischemic stroke is safe, feasible and demonstrated therapeutic efficacy to counteract neurological impairments driven by stroke. Namely, MSC induced immunomodulation, angiogenesis and both neuroprotection as well as the re-establishment of neural circuit. A summary of the reported clinical trials and a complete revision of the transplantation procedures, type MSC used, the most effective ways of administration and relevant therapeutic mechanisms can be found in [141] .

There is also registration of a Phase I open-label clinical trial that evaluated the efficacy of MSC in reducing seizure frequency in epileptic patients [142] (Table 1 ). A total of 12 patients were recruited and all received anti-epileptic drugs; from these, 10 were randomly treated with MSC. The authors reported that MSC injections were well tolerated and did not cause any severe adverse effects. Three out of 10 patients receiving MSC presented no seizures for more than one year and a higher percentage responded positively to anti-epileptic drugs than in the control group (5 out of 10 in treated group vs 2 out of 12 in controls, P = 0.0135).

Based on these studies, MSC can probably fight SARS-CoV-2 infection in the CNS and counteract its deleterious effects resembling what is here described for other neurological pathologies. However, clinical evidences in COVID-19 of this effect would be desired.

As conclusion, we suggest that MSC may offer good supportive treatment to COVID-19 patients, by both inhibiting overactivation of the immune system and repairing not only the lungs but also other crucial organs. However, despite these meaningful comparative studies, very little is still known about the mechanisms of SARS-CoV-2 infection in each organ and more descriptive studies are required to better understand the behavior of the virus. On the other hand, clinical studies are extremely important as they will allow (or not) for translation.

Supporting the possible implementation of MSC treatment in COVID-19, since the beginning of the outbreak four clinical studies and four case reports investigating MSC's therapeutic potential (and their derived products) to treat COVID-19 patients have been performed and already published their results [5] [6] [7] [8] [9] [10] [11] [12] . Moreover, several phase I or II clinical trials are currently ongoing (www.clinicaltrials.gov). Notably, there are also ongoing studies that will evaluate whether MSC-derived EVs or CM-MSC administration is safe and can ameliorate COVID-19 symptoms (NCT04276987, NCT04366063, NCT04398303, ChiCTR2000029569, ChiCTR2000030261). A concise review of both completed and ongoing clinical studies is given in Table 2 .

To date, clinical trials and case reports showed that MSC use in COVID-19 is safe as no major adverse effects directly related to MSC transplantation were reported. Additionally, MSC treatment was shown to promote patient's recovery, even in critically ill elders with comorbidities [5] [6] [7] [8] [9] [10] [11] . In these studies, moderate to critically ill COVID-19 patients were infused with MSC after they failed to improve, and symptoms worsened, under standard [5, 7] or other treatment conditions [6, 8, [6] [7] [8] [9] [10] [11] . So far, MSC transplantation seem to lead to clinical recovery of patients in relatively short time, showing amelioration of COVID-19 symptoms few days after MSC treatment. Indeed, MSC treatment alone or its combination with other therapies improved respiratory function and increased oxygenation [5] [6] [7] [8] [9] [10] [11] . Sánchez-Guijo and colleges demonstrated the effectiveness of MSC administration in 13 patients under invasive mechanical ventilation, as they improved the clinical status for 70 % of infected individuals and lead to the extubation of 53 % of them [11] . Additionally, a study that compared the mortality rate of patients treated with MSC or treated with standard conditions showed that while the control group had a mortality rate of 10.34 % 28-days after treatment, none of the MSC-infused patients perished [7] .

Importantly, these clinical studies underline MSC's modulation of the immune response as a key mechanism to avoid a cytokine storm which may be a crucial step in the treatment of COVID-19. Indeed, MSC reestablished the levels of lymphocytes counts [5] [6] [7] [8] [9] [10] [11] , T and Natural killer cells [6] and increased migration of DC to the site of inflammation [5] . Moreover, treatment with MSC decreased the levels of C-reactive protein and of pro-inflammatory cytokines and chemokines, such as TNF-α and IL-6 [5, 7, 8, 11] . In addition, MSC also lowered inflammation-induced lesion in the lungs [7] [8] [9] and promoted lung tissue repair with increased IL-10 and VEGF expression [5] . Notably, Leng and collaborators showed that MSC did not express ACE2 nor TMPRSS2, meaning they were naturally immune to SARS-CoV-2, reinforcing MSC as a feasible therapeutic agent [5] .

Overall, the published clinical trials and case reports followed similar approaches for the administration of MSC as the main or adjuvant therapy. In most cases 1 × 10 6 cells/ kg of body weight (though it ranged from 0.3− 2 × 10 6 cells/ kg) were IV delivered [5] [6] [7] [8] 10, 11] , with one exception in which the IV route was combined with intratracheal delivery [9] . From all the seven studies, four infused MSC derived from UC-MSC [6, 7, 9, 10] , one MSC derived from the AD-MSC [11] , one BM-MSC [5] and another MSC from menstrual blood [8] . The frequency of administration varied from study to study, or depended on patients' clinical conditions, with MSC being delivered one [5, 7, 11] , two [9, 11] or three times [8, 11] .

Furthermore, a prospective nonrandomized open-label cohort study demonstrated that the IV administration of exosomes derived from BM-MSC (ExoFlo™) is safe (with no therapy-related adverse events observed) and may also improve COVID-19 patient's condition [12] . From 24 severe COVID-19 patients that showed moderate-to-severe ARDS, 71 % of the patients recovered and were discharged 5.6 days after ExoFlo treatment on average; 14 % remained critically ill, but stable; and 16 % deceased. Thus, the survival rate was 83 %, higher than that estimated for patients in the same condition. Moreover, treatment restored patient's oxygenation. Similar to MSC transplantation, treatment with ExoFlo also improved inflammation, promoting a decrease in neutrophil count and lymphopenia and a significant reduction in C-reactive protein, ferritin and D-dimer.

The results obtained in these initial studies were encouraging, and very important to design future clinical studies. However, more doubleblind, placebo-controlled studies have to be performed to confirm MSC promising effects in COVID-19 treatment, and optimal therapeutic conditions have to be investigated. Importantly, large cohorts would be crucial to validate this therapeutic intervention in the future.

There are still some concerns regarding MSC application for therapeutic purposes, namely: 1) the fact that the precise mechanisms of MSC in COVID-19 patients are unknown and there is no robust pre-clinical model for COVID-19 that could facilitate research. 2) limited number of clinical trials including a high number of COVID-19 patients; 3) different clinical presentations; 4) the diversity of genetics and the consequent immune response in COVID-19 patients, 5) the presence of other associated comorbidities, challenging the gathering of clear conclusions regarding MSC outcomes in patients suffering from COVID-19.

However, based on beneficial evidence highlighted by either preclinical or clinical studies performed in inflammatory conditions which affect the main organs disturbed by SARS-CoV-2, and due to the lack of so far efficient treatments, it is reasonable to consider MSC therapy a feasible treatment. In that line, their compassionate use was already approved by the FDA for patients presenting ARDS with very bad prognosis. Moreover, a high number of clinical studies involving the use of MSC or medicines derived from these cells are presently running with the aim of introducing this treatment to critically ill COVID-19 patients in which especially severe impairment of pulmonary function is present. It must though be kept in mind that other organs can be severely damaged. So, it should be considered to expand their application to Covid-19 patients with other severe symptoms.

Accordingly, a high-grade clinical study, placebo-controlled, and ideally including patients from different countries would be crucial and should hence be performed. The highest well tolerated dose tested for ARDS could be used to treat COVID-19 patients [63, 143] . Regarding the type of cells, though UC-MSC or BM-MSC are the main sources used so far in clinical studies (www.clinicaltrials.gov), there is a lack of consensus on which source is more appropriate for the different conditions herein referred. Indeed, MSC from different sources may exhibit different therapeutic potentials. For example, UC-MSC are usually Most clinical trials include a control/placebo group except for the ones were this absence is mentioned. List of abbreviations: ACE2 -angiotensin-converting enzyme-2; AI -aerosol inhalation; AZ -Azithromycin; AD-MSCadipose tissue-derived mesenchymal stromal cells; BM-MSCbone marrow-derived mesenchymal stromal cells; hCT-MSChuman Cord Tissue-derived mesenchymal stromal cells; DP-MSC -dental pulp-derived associated with a greater immunomodulatory action [144] . Therefore, a clarification on the best cell source for each clinical case of COVID-19 could help improving therapeutic outcomes. Despite the fact that different administrations routes can offer advantages for specific organs, the systemic injection may be the most appropriate for COVID-19 patients since it allows MSC to spread throughout the whole body and target several affected organs. Indeed, Lu and colleagues showed that upon IV administration in ARDS mice, MSC tend to accumulate mainly in the lungs, but also reached the liver, kidney, spleen, heart, and brain [145] . Moreover, MSC administration may be combined with other drugs or therapeutic strategies in order to obtain a synergistic multidirectional effect in COVID-19 patients. This has been tested in some clinical trials ( Table 2) .

Because studies comparing the efficacy of MSC and their secretome/ EVs are missing, it is not clear which kind of therapy should be used. However, as some studies reported the importance of direct cellular contact for therapeutic success [53, 54, 59, 113, 146] , and given the urgent character of applicability of the treatment, it makes sense to start by directly using MSC. Notwithstanding, both kind of therapies can possibly be admitted, as was demonstrated by the clinical studies in COVID-19 patients.

The potential advantage of using MSC to treat SARS-CoV-2-infected patients is the fact that they can target different organs simultaneously and have a pleiotropic action aimed at counteracting infection, repairing damaged tissues and avoiding invasion from other opportunistic agents. When thinking of a therapy for COVID-19 we should not look into the human body as a compartmentalized structure; but as a whole instead, where every single structure is connected to each other strongly depending on their interplay.

In order to rationally improve therapies for COVID-19, more research is required aiming at characterizing the mechanisms underlining MSC immunomodulatory capacity and defining the microenvironment expressed in different SARS-CoV-2 scenarios [147] . Clinical studies that were reported so far are extremely important as they shed light on the possible future application of MSC to COVID-19 patients not only suffering from ARDS, but also from other organ failures. We expect that the presently undertaking clinical studies can also give a precious input into the field.

Maria Inês Barros -discussion and paper writing, figure design; António Dinis da Silva -discussion and paper writing; Luís Pereira de Almeidapaper discussion and reviewing; Catarina Oliveira Mirandapaper outline, discussion and paper writing, and reviewing.

The authors report no declarations of interest.

Inês Barros earned a MSc in Pharmaceutical Biotechnology from University of Coimbra, Portugal. She is studying potential Mesenchymal Stromal Cell and its derived products in the treatment of a neurodegenerative disorder during her Ph.D. in Experimental Biology and Biomedicine. Currently she is integrated in the laboratory of Professor Luís Pereira de Almeida at Center for Neuroscience and Cell Biology, University of Coimbra, Portugal António da Silva received his bachelor in Biochemistry at the Faculty of Sciences and Technology of the University of Coimbra (FCTUC), Portugal. He is currently enrolled in a master's degree on Molecular Cell Biology at the same institute while participating in a project regarding the effects of mesenchymal stromal cells on neurodegenerative disorders at the laboratory of Professor Luís Pereira de Almeida at Center for Neuroscience and Cell Biology, University of Coimbra, Portugal.

Luís Pereira de Almeida received his Ph.D. in Pharmaceutics from the University of Coimbra, Portugal in 2003. He is presently Professor at the Faculty of Pharmacy, University of Coimbra since 2003, with tenure since 2008, teaches at graduate and undergraduate levels, coordinated the Doctoral Programme in Experimental Biology and Biomedicine and the Masters in Pharmaceutical Biotechnology. His research activity is developed at the Center for Neuroscience and Cell Biology of the University of Coimbra (CNC), Portugal where he is principal investigator and President. He Coordinates the Center for Innovative Biomedicine and Biotechnology https://www.cibb. uc.pt/, a large biomedical center, which integrates CNC and iCBR instititutes. He spent short sabbatical leaves at CEA, Saclay in France (2005) and at the Massachussetts Institute of Technology (2010).

Catarina Miranda earned her master's degree in the Faculty of Sciences and Technology of the University of Coimbra (FCTUC), Portugal and a Ph.D. from Instituto de Ciências Abel Salazar, University of Porto, Portugal. Since then has been developing research within the field of stem cell therapy. She did her postdoctoral training in the laboratory of Professor Luís Pereira de Almeida at Center for Neuroscience and Cell Biology, University of Coimbra, Portugal, where she is currently Investigator. Her work is now focused on therapies for brain disorders based on mesenchymal stromal cells.

COVID-19 infection: the perspectives on immune responses

Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19)

Central nervous system manifestations of COVID-19: a systematic review

Immunomodulation by mesenchymal stem cells (MSCs): mechanisms of action of living, apoptotic, and dead MSCs

Transplantation of ACE2(-) mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia

Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells

Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells

Clinical study using mesenchymal stem cells for the treatment of patients with severe COVID-19

Mesenchymal stem cell treatment in a critically ill COVID-19 patient: a case report

Human umbilical cord mesenchymal stem cells for adjuvant treatment of a critically ill COVID-19 patient: a case report

Adipose-derived mesenchymal stromal cells for the treatment of patients with severe SARS-CoV-2 pneumonia requiring mechanical ventilation

Exosomes derived from bone marrow mesenchymal stem cells as treatment for severe COVID-19

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

The SARS-CoV-2 outbreak: what we know

RNA based mNGS mesenchymal stromal cells; MB-MSC -menstrual blood-derived mesenchymal stromal cells

OM-MSC -olfactory mucosa-derived mesenchymal stem cells; UC-MSC -umbilical cord-derived mesenchymal stromal cells; CM -conditioned media; ChiCTR -Chinese Clinical Trial Registry

NA -Not Applicable; NR -Not Reported; SP-D -surfactant protein D. #Autologous cell infusion

Allogeneic ex vivo expanded placental mesenchymal-like adherent stromal cell. approach identifies a novel human coronavirus from two individual pneumonia cases in 2019 Wuhan outbreak

Complete genome characterisation of a novel coronavirus associated with severe human respiratory disease in Wuhan, China. Book Complete Genome Characterisation of a Novel Coronavirus

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis

Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese center for disease control and prevention

Understanding the neurotropic characteristics of SARS-CoV-2: from neurological manifestations of COVID-19 to potential neurotropic mechanisms

Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19

The cytokine storm in COVID-19: an overview of the involvement of the chemokine/chemokinereceptor system

The pivotal link between ACE2 deficiency and SARS-CoV-2 infection

Identifying airborne transmission as the dominant route for the spread of COVID-19

Update on treatment of COVID-19: ongoing studies between promising and disappointing results

A global treatments for coronaviruses including COVID-19

Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Remdesivir for the treatment of Covid-19 -final report

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime

Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement

Low immunogenicity of allogeneic human umbilical cord blood-derived mesenchymal stem cells in vitro and in vivo

Effect of the microenvironment on mesenchymal stem cell paracrine signaling: opportunities to engineer the therapeutic effect

A critical role of IFNgamma in priming MSC-mediated suppression of T cell proliferation through up-regulation of B7-H1

Stem cell transplantation: the lung barrier

Mesenchymal stem cell-derived extracellular vesicles: toward cell-free therapeutic applications

ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia

Clinical features of patients infected with 2019 novel coronavirus in

The acute respiratory distress syndrome

Mesenchymal stem cells: mechanisms of potential therapeutic benefit in ARDS and sepsis

Mesenchymal stromal cells attenuate infection-induced acute respiratory distress syndrome in animal experiments: a meta-analysis

Mesenchymal stromal cell treatment prevents H9N2 avian influenza virus-induced acute lung injury in mice

Bone marrow stromal cells attenuate sepsis via prostaglandin E (2)-dependent reprogramming of host macrophages to increase their interleukin-10 production

Activation of human mesenchymal stem cells impacts their therapeutic abilities in lung injury by increasing interleukin (IL)-10 and IL-1RN levels

Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury

Human multipotent stromal cells attenuate lipopolysaccharide-induced acute lung injury in mice via secretion of tumor necrosis factor-alpha-induced protein 6

Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37

Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis

Therapeutic effects of human mesenchymal stem cells in ex vivo human lungs injured with live bacteria

Mesenchymal stem cells enhance survival and bacterial clearance in murine Escherichia coli pneumonia

Analysis of mitochondrial transfer in direct Co-cultures of human monocyte-derived macrophages (MDM) and mesenchymal stem cells (MSC)

Mesenchymal stromal cells modulate macrophages in clinically relevant lung injury models by extracellular vesicle mitochondrial transfer

Conditioned media from mesenchymal stromal cells restore sodium transport and preserve epithelial permeability in an in vitro model of acute alveolar injury

Therapeutic implications of human umbilical cord mesenchymal stromal cells in attenuating influenza a(H5N1) virus-associated acute lung injury

Prevention of LPS-induced acute lung injury in mice by mesenchymal stem cells overexpressing angiopoietin 1

Therapeutic effects of human mesenchymal stem cellderived microvesicles in severe pneumonia in mice

Mitochondrial transfer from bonemarrow-derived stromal cells to pulmonary alveoli protects against acute lung injury

Bone marrow-derived mesenchymal stem cells enhance autophagy via PI3K/AKT signalling to reduce the severity of ischaemia/reperfusion-induced lung injury

Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study

In vivo effects of mesenchymal stromal cells in two patients with severe acute respiratory distress syndrome

Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial

Clinical study of mesenchymal stem cell treating acute respiratory distress syndrome induced by epidemic Influenza A (H7N9) infection, a hint for COVID-19 treatment

Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial

Cell therapy in acute respiratory distress syndrome

Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19

Cell-based therapy to reduce mortality from COVID-19: systematic review and meta-analysis of human studies on acute respiratory distress syndrome

Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic

COVID-19 and acute myocardial injury: the heart of the matter or an innocent bystander?

COVID-19 and cardiovascular disease

Acute coronary syndromes and Covid-19: exploring the uncertainties

COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection

Association of cardiac infection with SARS-CoV-2 in confirmed COVID-19 autopsy cases

Antiarrhythmic potential of mesenchymal stem cell is modulated by hypoxic environment

Hypoxia inducible factor-1alpha potentiates jagged 1-mediated angiogenesis by mesenchymal stem cell-derived exosomes

Intravenous mesenchymal stem cell-derived exosomes ameliorate myocardial inflammation in the dilated cardiomyopathy

Adipose tissue-derived stem cells suppress coronary arteritis of Kawasaki disease in vivo

Mesenchymal stem cells improve murine acute coxsackievirus B3-induced myocarditis

Exosomes derived from umbilical cord mesenchymal stem cells alleviate viral myocarditis through activating AMPK/mTOR-mediated autophagy flux pathway

Clinical studies of cell therapy in cardiovascular medicine: recent developments and future directions

Concise review: mesenchymal stem cells in cardiovascular regeneration: emerging research directions and clinical applications

Efficacy of mesenchymal stem cell therapy in systolic heart failure: a systematic review and meta-analysis

Safety and efficacy of adult stem cell therapy for acute myocardial infarction and ischemic heart failure (SafeCell heart): a systematic review and meta-analysis

Recapitulation of SARS-CoV-2 infection and cholangiocyte damage with human liver ductal organoids

Liver injury during highly pathogenic human coronavirus infections

Specific ACE2 Expression in Cholangiocytes May Cause Liver Damage After 2019-nCoV Infection

Mesenchymal stem cells alleviate experimental autoimmune cholangitis through immunosuppression and cytoprotective function mediated by galectin-9

Effects of human amnion-derived mesenchymal stem cells and conditioned medium in rats with sclerosing cholangitis

Human mesenchymal stem cells for hepatitis B virus-related acute-on-chronic liver failure: a systematic review with meta-analysis

Fibrosing cholestatic hepatitis: clinicopathologic spectrum, diagnosis and pathogenesis

Endothelial cell infection and endotheliitis in COVID-19

Acute kidney injury in patients hospitalized with COVID-19

Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection

COVID-19-associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup

Mesenchymal stem cell therapy in acute kidney injury (AKI): review and perspectives

Mesenchymal stem cells-potential applications in kidney diseases

Mesenchymal stem cell-derived microvesicles protect against acute tubular injury

AKI recovery induced by mesenchymal stromal cell-derived extracellular vesicles carrying MicroRNAs

Exosome and microvesicle-enriched fractions isolated from mesenchymal stem cells by gradient separation showed different molecular signatures and functions on renal tubular epithelial cells

Protective actions of administered mesenchymal stem cells in acute kidney injury: relevance to clinical trials

Allogeneic mesenchymal stem cells for treatment of AKI after cardiac surgery

COVID-19 and the gastrointestinal tract: more than meets the eye

GI symptoms as early signs of COVID-19 in hospitalised Italian patients

Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection

Novelty in the gut: a systematic review and metaanalysis of the gastrointestinal manifestations of COVID-19

Alterations in gut microbiota of patients with COVID-19 during time of hospitalization

Persistent viral shedding of SARS-CoV-2 in faeces -a rapid review

SARS-CoV-2 productively infects human gut enterocytes

Mesenchymal stem cells (MSC) derived from induced pluripotent stem cells (iPSC) equivalent to adipose-derived MSC in promoting intestinal healing and microbiome normalization in mouse inflammatory bowel disease model

Mesenchymal stem cell-gut microbiota interaction in the repair of inflammatory bowel disease: an enhanced therapeutic effect

Conditioned mesenchymal stem cells produce pleiotropic gut trophic factors

Ex vivo immunosuppressive effects of mesenchymal stem cells on Crohn's disease mucosal T cells are largely dependent on indoleamine 2,3-dioxygenase activity and cell-cell contact

CCL2 and CXCL12 derived from mesenchymal stromal cells cooperatively polarize IL-10+ tissue macrophages to mitigate gut injury

Mesenchymal stem cell-derived exosomes and other extracellular vesicles as new remedies in the therapy of inflammatory diseases

Regulatory dendritic cells induced by mesenchymal stem cells ameliorate dextran sodium sulfateinduced chronic colitis in mice

Adipose stromal cells mediated switching of the pro-inflammatory profile of M1-like macrophages is facilitated by PGE2: in vitro evaluation

A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn's disease refractory to biologic therapy

The safety of autologous and metabolically fit bone marrow mesenchymal stromal cells in medically refractory Crohn's disease -a phase 1 trial with three doses

SARS-CoV-2: olfaction, brain infection, and the urgent need for clinical samples allowing earlier virus detection

Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host-virus interaction, and proposed neurotropic mechanisms

Neuropilin1 as a new potential SARSCoV2 infection mediator implicated in the neurologic features and central nervous system involvement of COVID19

COVID-19-associated acute hemorrhagic necrotizing encephalopathy: imaging features

Blood brain barrier: a review of its anatomy and physiology in health and disease

The pericyte-a review

Infection and upregulation of proinflammatory cytokines in human brain vascular pericytes by human cytomegalovirus

Infection of human pericytes by HIV-1 disrupts the integrity of the blood-brain barrier

Occludin controls HIV transcription in brain pericytes via regulation of SIRT-1 activation

Infection of pericytes in vitro by Japanese encephalitis virus disrupts the integrity of the endothelial barrier

Dysfunction of brain pericytes in chronic neuroinflammation

Adiposederived mesenchymal stem cells reduce neuronal death after transient global cerebral ischemia through prevention of blood-brain barrier disruption and endothelial damage

Mesenchymal stem cells maintain blood-brain barrier integrity by inhibiting aquaporin-4 upregulation after cerebral ischemia

Diffuse and persistent blood-spinal cord barrier disruption after contusive spinal cord injury rapidly recovers following intravenous infusion of bone marrow mesenchymal stem cells

Early single-dose treatment with exosomes provides neuroprotection and improves blood-brain barrier integrity in swine model of traumatic brain injury and hemorrhagic shock

The inhibitory effect of mesenchymal stem cell on blood-brain barrier disruption following intracerebral hemorrhage in rats: contribution of TSG-6

Mesenchymal stem cells alleviate Japanese encephalitis virus-induced neuroinflammation and mortality

Mesenchymal stromal cells protect against vascular damage and depression-like behavior in mice surviving cerebral malaria

Mesenchymal stromal cells modulate peripheral stress-induced innate immune activation indirectly limiting the emergence of neuroinflammation-driven depressive and anxiety-like behaviors

Adipose-derived mesenchymal stem cells protect against CMS-induced depression-like behaviors in mice via regulating the Nrf2/HO-1 and TLR4/NF-kappaB signaling pathways

Acute cerebrovascular disease following COVID-19: a single center, retrospective, observational study

Mesenchymal stem cell therapy for ischemic stroke: a look into treatment mechanism and therapeutic potential

Treatment of refractory epilepsy patients with autologous mesenchymal stem cells reduces seizure frequency: an open label study

Mesenchymal stem cell infusion shows promise for combating coronavirus (COVID-19)-induced pneumonia

What makes umbilical cord tissue-derived mesenchymal stromal cells superior immunomodulators when compared to bone marrow derived mesenchymal stromal cells?

Pulmonary retention of adipose stromal cells following intravenous delivery is markedly altered in the presence of ARDS

Immunoregulatory potential of mesenchymal stem cells following activation by macrophage-derived soluble factors

Mesenchymal stem cells-bridge catalyst between innate and adaptive immunity in COVID 19

Our group is supported by the European Regional Development Fund through the Regional Operational Program Center2020, Competitiveness Factors Operational Program (COMPETE 2020) and National Funds through Foundation for Science and Technology (FCT): Brain-Health2020 projects (CENTRO-01-0145-FEDER-000008), ViraVector We would like to thank to Peter Valente for English revision.